{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:41:57Z","timestamp":1791661317930,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","award":["Ionis Pharmaceuticals"],"award-info":[{"award-number":["Ionis Pharmaceuticals"]}],"id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hereditary angioedema (HAE) is a rare, autosomal dominant disorder causing swelling attacks in various parts of the body, resulting in symptoms and impacts on health-related quality of life (HRQoL). The symptoms and impacts on HRQoL have been well-documented; however, they are based on samples of participants who are primarily White. The objective of this qualitative interview study was to explore the patient experience of HAE among a racially diverse sample of adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a non-interventional, qualitative study that involved adults with HAE. A purposive sampling strategy was used to recruit 16 adults with HAE, with a target of at least 8 who were non-White. All participants completed a one-time, one-on-one, 60-minute, remote interview. Interview data were coded and analyzed using qualitative data analysis software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen adults took part in the study, with three-quarters of the sample self-identifying as non-White. Participants described experiencing common symptoms of HAE attacks: swelling, general discomfort, vomiting, nausea, fatigue, diarrhea, rash (or change in skin), feeling lightheaded, tingling sensation, and itching. They experienced attacks in various bodily locations, with all reporting abdominal attacks, and most reporting attacks in the feet, hands, and face. Of these, laryngeal, abdominal, and facial attacks were generally considered more severe. Participants reported impacts associated with HAE and HAE attacks across 7 domains of HRQoL: emotional, physical, social, and cognitive functioning; work or school; sleep-related problems; and finances. They also identified ways in which some attack triggers, namely food-related triggers and attacks triggered by injury or repeated physical activity, impacted HRQoL. Overall, participants reported satisfaction with both current prophylactic and acute treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To understand the patient experience of any health condition, it is essential that the experiences of patients from diverse backgrounds are included. Findings from this qualitative study demonstrate that key experiences and impacts of HAE in a diverse sample of adults was similar to that described in previously published studies with predominantly White patient samples. This addresses a critical research gap to support the development of measurement strategies that are inclusive of patient experiences, including impacts on HRQoL, in diverse populations of patients with HAE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04254-0","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:45:10Z","timestamp":1770320710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The patient experience of hereditary angioedema: findings from a racially diverse sample of adult patients"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8783-9877","authenticated-orcid":false,"given":"Lynne","family":"Broderick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April M.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Tesler","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bordone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Yarlas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"3","key":"4254_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.anai.2025.05.018","volume":"135","author":"AJ Castaldo","year":"2025","unstructured":"Castaldo AJ, Wells KE, Khalid S, et al. Establishing a hereditary angioedema prevalence for the united States using a large administrative claims database. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2025;135(3):303\u201310. https:\/\/doi.org\/10.1016\/j.anai.2025.05.018.","journal-title":"Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol"},{"issue":"8","key":"4254_CR2","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1016\/j.jaip.2023.01.023","volume":"11","author":"MA Riedl","year":"2023","unstructured":"Riedl MA, Danese M, Danese S, Ulloa J, Maetzel A, Audhya PK. Hereditary angioedema with normal C1 inhibitor: US survey of prevalence and provider practice patterns. J Allergy Clin Immunol Pract. 2023;11(8):2450\u2013e24566. https:\/\/doi.org\/10.1016\/j.jaip.2023.01.023.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"4254_CR3","doi-asserted-by":"publisher","first-page":"AB137","DOI":"10.1016\/j.jaci.2022.12.429","volume":"151","author":"J Anderson","year":"2023","unstructured":"Anderson J, Craig T, Mellor J, et al. Comparison of hereditary angioedema among patients of different races and ethnicities in the united states: data from a Real-World study. J Allergy Clin Immunol. 2023;151(2):AB137. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.429.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"4254_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13223-021-00550-5","volume":"17","author":"J Anderson","year":"2021","unstructured":"Anderson J, Levy DS, Lumry W, Koochaki P, Lanar S, Henry Li H. Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy. Allergy Asthma Clin Immunol. 2021;17(1):60. https:\/\/doi.org\/10.1186\/s13223-021-00550-5.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"4254_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12016-021-08850-9","volume":"61","author":"Z Balla","year":"2021","unstructured":"Balla Z, Ign\u00e1cz B, Varga L, K\u0151halmi KV, Farkas H. How angioedema quality of life questionnaire can help physicians in treating C1-Inhibitor deficiency patients? Clin Rev Allergy Immunol. 2021;61(1):50\u20139. https:\/\/doi.org\/10.1007\/s12016-021-08850-9.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"4254_CR6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","volume":"124","author":"A Banerji","year":"2020","unstructured":"Banerji A, Davis KH, Brown TM, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600\u20137. https:\/\/doi.org\/10.1016\/j.anai.2020.02.018.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"4254_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13223-021-00563-0","volume":"17","author":"J Hews-Girard","year":"2021","unstructured":"Hews-Girard J, Goodyear MD. Psychosocial burden of type 1 and 2 hereditary angioedema: a single-center Canadian cohort study. Allergy Asthma Clin Immunol. 2021;17(1):61. https:\/\/doi.org\/10.1186\/s13223-021-00563-0.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"4254_CR8","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14680","volume":"76","author":"WR Lumry","year":"2021","unstructured":"Lumry WR, Weller K, Magerl M, et al. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. Allergy. 2021;76(4):1188\u201398. https:\/\/doi.org\/10.1111\/all.14680.","journal-title":"Allergy"},{"issue":"1","key":"4254_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13023-020-01658-4","volume":"16","author":"WR Lumry","year":"2021","unstructured":"Lumry WR, Zuraw B, Cicardi M, et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet J Rare Dis. 2021;16(1):86. https:\/\/doi.org\/10.1186\/s13023-020-01658-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"4254_CR10","doi-asserted-by":"publisher","first-page":"100792","DOI":"10.1016\/j.waojou.2023.100792","volume":"16","author":"J Raasch","year":"2023","unstructured":"Raasch J, Glaum MC, O\u2019Connor M. The multifactorial impact of receiving a hereditary angioedema diagnosis. World Allergy Organ J. 2023;16(6):100792. https:\/\/doi.org\/10.1016\/j.waojou.2023.100792.","journal-title":"World Allergy Organ J"},{"issue":"3","key":"4254_CR11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s12325-022-02401-0","volume":"40","author":"ES Sinnathamby","year":"2023","unstructured":"Sinnathamby ES, Issa PP, Roberts L, et al. Hereditary angioedema: Diagnosis, clinical Implications, and pathophysiology. Adv Ther. 2023;40(3):814\u201327. https:\/\/doi.org\/10.1007\/s12325-022-02401-0.","journal-title":"Adv Ther"},{"issue":"1","key":"4254_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","volume":"17","author":"K Bork","year":"2021","unstructured":"Bork K, Anderson JT, Caballero T, et al. Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy Asthma Clin Immunol. 2021;17(1):40. https:\/\/doi.org\/10.1186\/s13223-021-00537-2.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"4254_CR13","doi-asserted-by":"publisher","first-page":"100758","DOI":"10.1016\/j.waojou.2023.100758","volume":"16","author":"HJ Chong-Neto","year":"2023","unstructured":"Chong-Neto HJ. A narrative review of recent literature of the quality of life in hereditary angioedema patients. World Allergy Organ J. 2023;16(3):100758. https:\/\/doi.org\/10.1016\/j.waojou.2023.100758.","journal-title":"World Allergy Organ J"},{"issue":"1","key":"4254_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-021-01717-4","volume":"16","author":"J Mendivil","year":"2021","unstructured":"Mendivil J, Murphy R, De La Cruz M, et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey. Orphanet J Rare Dis. 2021;16(1):94. https:\/\/doi.org\/10.1186\/s13023-021-01717-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4254_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaci.2023.09.039","volume":"153","author":"D Honda","year":"2024","unstructured":"Honda D, Li PH, Jindal AK, et al. Uncovering the true burden of hereditary angioedema due to C1-inhibitor deficiency: A focus on the Asia-Pacific region. J Allergy Clin Immunol. 2024;153(1):42\u201354. https:\/\/doi.org\/10.1016\/j.jaci.2023.09.039.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"4254_CR16","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014The 2021 revision and update. Allergy. 2022;77(7):1961\u201390. https:\/\/doi.org\/10.1111\/all.15214.","journal-title":"Allergy"},{"issue":"12","key":"4254_CR17","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1016\/j.jaip.2021.08.019","volume":"9","author":"S Sylvestre","year":"2021","unstructured":"Sylvestre S, Craig T, Ajewole O, Craig S, Kaur S, Al-Shaikhly T. Racial and ethnic disparities in the research and care of hereditary angioedema patients in the united States. J Allergy Clin Immunol Pract. 2021;9(12):4441\u2013e44492. https:\/\/doi.org\/10.1016\/j.jaip.2021.08.019.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"4254_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s41687-023-00576-w","volume":"7","author":"M Vanya","year":"2023","unstructured":"Vanya M, Watt M, Shahraz S, et al. Content validation and psychometric evaluation of the angioedema quality of life questionnaire for hereditary angioedema. J Patient-Rep Outcomes. 2023;7(1):33. https:\/\/doi.org\/10.1186\/s41687-023-00576-w.","journal-title":"J Patient-Rep Outcomes"},{"key":"4254_CR19","doi-asserted-by":"publisher","unstructured":"Craig T, Baptist AP, Anderson J, et al. Hereditary angioedema: patient healthcare experiences within underrepresented racial and ethnic groups in the United States. Ann Allergy Asthma Immunol. Published Online January. 2025;S1081120625000080. https:\/\/doi.org\/10.1016\/j.anai.2025.01.007.","DOI":"10.1016\/j.anai.2025.01.007"},{"key":"4254_CR20","unstructured":"U.S. Food and Drug Administration. Patient-Focused Drug Development: collecting comprehensive and representative input. Published online 2020."},{"key":"4254_CR21","unstructured":"U.S. Food and Drug Administration. Patient-Focused Drug Development: methods to identify what is important to patients. Published online 2022."},{"key":"4254_CR22","unstructured":"U.S. Food and Drug Administration. Patient-Focused Drug Development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. Published online 2022."},{"issue":"1","key":"4254_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13023-025-03539-0","volume":"20","author":"L Broderick","year":"2025","unstructured":"Broderick L, Foster A, Waldman LT, Bordone L, Yarlas A. The adolescent experience of hereditary angioedema: a qualitative study of disease burden and treatment experience. Orphanet J Rare Dis. 2025;20(1):16. https:\/\/doi.org\/10.1186\/s13023-025-03539-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4254_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41687-025-00876-3","volume":"9","author":"L Broderick","year":"2025","unstructured":"Broderick L, Foster A, Waldman LT, Jacobs KD, Bordone L, Yarlas A. Content validation of the angioedema quality of life questionnaire (AE-QoL) in a population of adult and adolescent patients with hereditary angioedema (HAE). J Patient-Rep Outcomes. 2025;9(1):42. https:\/\/doi.org\/10.1186\/s41687-025-00876-3.","journal-title":"J Patient-Rep Outcomes"},{"issue":"8","key":"4254_CR25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377. https:\/\/doi.org\/10.1016\/j.jval.2011.06.014.","journal-title":"Value Health"},{"issue":"1","key":"4254_CR26","first-page":"48","volume":"121","author":"H Zafra","year":"2022","unstructured":"Zafra H. Hereditary angioedema: A review. WMJ Off Publ State Med Soc Wis. 2022;121(1):48\u201353.","journal-title":"WMJ Off Publ State Med Soc Wis"},{"key":"4254_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-9-44","volume":"9","author":"Z Zotter","year":"2014","unstructured":"Zotter Z, Csuka D, Szab\u00f3 E, et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2014;9:44. https:\/\/doi.org\/10.1186\/1750-1172-9-44.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"4254_CR28","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.jaip.2023.03.006","volume":"11","author":"NS Arora","year":"2023","unstructured":"Arora NS, Nelson B, Carpenter L, et al. Consequences of insurance coverage delays and denials for patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2023;11(8):2432\u2013e24381. https:\/\/doi.org\/10.1016\/j.jaip.2023.03.006.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"4254_CR29","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.anai.2010.01.024","volume":"104","author":"DA Wilson","year":"2010","unstructured":"Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2010;104(4):314\u201320. https:\/\/doi.org\/10.1016\/j.anai.2010.01.024.","journal-title":"Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04254-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04254-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04254-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:37:22Z","timestamp":1781631442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04254-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4254"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04254-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was granted ethics approval by WCG IRB (IRB tracking number: 20240994). WCG IRB granted a waiver of documentation of signed consent for this study, though interviewers collected verbal consent prior to the start of each interview.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Laura Bordone, Jordan Valentine, and Aaron Yarlas are current employees of Ionis Pharmaceuticals, Inc. Lynne Broderick and April Foster are employees of IQVIA Quality Metric, Inc (QM), and Laura Tesler Waldman was an employee of QM at the time of the study and when the manuscript was drafted. QM was contracted by Ionis Pharmaceuticals, Inc. to carry out this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"92"}}